



Aclaris Therapeutics to Attend Upcoming Investor Conferences

November 2, 2018

WAYNE, Pa., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunology, today announced that management will attend the following conferences:

- Dr. Neal Walker, President and Chief Executive Officer, will present at the Credit Suisse 27th Annual Healthcare Conference in Scottsdale, AZ on Thursday, November 15, 2018 at 8:00 AM MST. Management will also host investor meetings on Thursday, November 15, 2018.
- Dr. Neal Walker, President and Chief Executive Officer, will present at the Evercore ISI Healthcare Conference in Boston, MA on Tuesday, November 27, 2018 at 3:05 PM EST. Management will also host investor meetings on Tuesday, November 27, 2018.
- Dr. Neal Walker, President and Chief Executive Officer, will present at the 30th Annual Piper Jaffray Healthcare Conference in New York, NY on Wednesday, November 28, 2018 at 3:30 PM EST. Management will also host investor meetings on Wednesday, November 28, 2018.

A live webcast of the Credit Suisse 27th Annual Healthcare Conference, Evercore ISI Healthcare Conference, and the 30th Annual Piper Jaffray Healthcare Conference presentations may be accessed through the Company's web site, www.aclaristx.com, on the 'Events and Presentations' section. An archived version of the presentation will be available for 30 days.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology, and immunology. Aclaris' focus on market segments with no FDA-approved medications or where treatment gaps exist has resulted in the first FDA-approved treatment for raised seborrheic keratoses and several clinical programs to develop medications for the potential treatment of common warts, alopecia areata, and vitiligo. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.

Contact:

Aclaris Contact
Michael Tung, M.D.
Senior Vice President
Corporate Strategy/Investor Relations
484-329-2140
mtung@aclariastx.com

Media Contact
Sheila Kennedy
Vice President, Corporate Communications
484-321-5559
media@aclariastx.com



Source: Aclaris Therapeutics, Inc.